iThriveMD Review: Questions to Settle Before Choosing a GLP-1 Plan

Before choosing an iThriveMD plan, ask the clinic to identify exactly which offer it is quoting. Its public documentation describes standard weight-loss treatment, tirzepatide microdosing and semaglutide maintenance, alongside monthly offers and longer packages. Those are not interchangeable choices. They carry different advertised prices, consultation details and enrollment requirements, while references to months, prepaid weeks and 28-day cycles make a written, program-specific explanation especially useful.

iThriveMD presents itself as a longevity-focused medical clinic addressing concerns including weight gain, fatigue and hormonal changes. This review examines what its public documentation lets prospective patients establish—and what still needs a direct answer—rather than recommending a medicine or predicting results. The pages were consulted October 19, 2026; some were available through saved copies collected earlier that day. Our starting questions for a GLP-1 program can help organize the initial conversation, but the important differences here are specific to iThriveMD.

At a glance

Documented medicines: iThriveMD offers compounded semaglutide and tirzepatide administered by subcutaneous injection. Its microdosing option is limited to tirzepatide.
Sources: [13]
Geographic access: The clinic advertises telehealth across California and Arizona with the same member pricing; Scottsdale is listed as a telehealth appointment rather than a documented physical clinic.
Sources: [10] [9]
Introductory monthly offers: Compounded injectable semaglutide is advertised at $199 initially, then $299 per month; compounded injectable tirzepatide at $299 initially, then $399 per month. The offers state billing every 28 days, and the $100 discount applies only to the first month, not packages.
Sources: [7] [8] [10]
Different testing statements: The homepage promises baseline labs before any plan begins, while the microdosing page says no particular BMI or lab work is required to enroll.
Sources: [10] [6]
Renewal responsibility: The homepage says packages are paid in full at purchase and automatically renew at the selected interval, while product pages offer payment plans. Cancellation, refund and financing details were not established in the consulted documentation.
Sources: [10] [7] [8] [6] [5]

Which iThriveMD service are you actually considering?

iThriveMD is broader than a single-drug subscription. Its weight-loss materials also mention B12 injections, IV therapy, hormone replacement therapy and advanced diagnostic testing. The general GLP page describes compounded semaglutide and tirzepatide, with the medical team recommending an option based on health profile and goals. A useful opening question is whether the proposed purchase is a weight-loss program, a maintenance arrangement or the separate microdosing service—and which associated services, if any, belong in that purchase.

The distinctions are explicit in some places. iThriveMD says only tirzepatide is available through its microdosing protocols, while semaglutide maintenance plans are offered to people who have completed a full GLP weight-loss program. Its general medication page describes small subcutaneous injections. None of those statements establishes an individual prescription, the exact preparation a particular patient would receive, or the amount supplied with a package. Ask for those particulars before treating two advertised offers as equivalent.

The clinic also publishes a team roster: Samir Damani, MD, is identified as founder and cardiovascular specialist; Aubrey Anderson and Thomas Macsay are identified as naturopathic doctors, with Macsay also listed as vice president of clinical operations. These are provider-published credentials, not independent license verification. Ask who will conduct your consultation, who can prescribe in your state and who handles follow-up. A listed team member is not necessarily the clinician assigned to your care.

Sources: [11] [13] [12]

What will the first payment—and the next one—cover?

The monthly advertisements are fairly specific about the introductory discount: $100 off the first month only, excluding package purchases. Semaglutide starts at the advertised $199 offer and then lists $299 per month; tirzepatide lists $299 initially and $399 afterward. Both say billing occurs every 28 days and describe no long-term commitment. That is a four-week billing interval, not a calendar month. Ask for the actual first and second charge dates rather than relying on the word “monthly.”

Longer offers need a more careful reading. The standard medication cards display the figures below beside monthly-savings language, but the consulted material does not unambiguously state the total collected for each package. It describes 12, 24 or 48 weeks paid upfront, shipping every 28 days, and an available payment plan. The homepage separately says all packages are paid in full at purchase. Obtain a checkout quote showing the full charge or financing arrangement, not just the prominent advertised figure.

The provider advertises semaglutide discounts of 10%, 15% and 20%, with claimed monthly savings of $29.90, $44.85 and $59.80. For tirzepatide, it advertises 25%, 35% and 50%, with claimed monthly savings of $99.75, $139.65 and $199.50. These are iThriveMD’s commercial comparisons, not independently calculated savings. Our questions beyond the monthly price are useful here: establish the billing unit, included services and total purchase obligation before comparing offers.

Advertised standard compounded injectable offers; package figures are displayed amounts, not verified upfront totals.
Offer and timing	Semaglutide	Tirzepatide
Monthly; billed every 28 days	$199 first-month promotion; $299 per month afterward; no long-term commitment	$299 first-month promotion; $399 per month afterward; no long-term commitment
“3-month”; 12 weeks paid upfront; ships every 28 days; payment plan available	$269.10 displayed; 10% off	$299.25 displayed; 25% off
“6-month”; 24 weeks paid upfront; ships every 28 days; payment plan available	$254.15 displayed; 15% off	$259.35 displayed; 35% off
“12-month”; 48 weeks paid upfront; ships every 28 days; payment plan available	$239.20 displayed; 20% off	$199.50 displayed; 50% off

Sources: [7] [8] [10] [5]

Does the microdosing offer answer a different question?

The microdosing page provides explicit package totals: $585 for 12 prepaid weeks, advertised as $195 per month; $1,053 for 24 prepaid weeks, advertised as $175.50 per month; and $1,755 for 48 prepaid weeks, advertised as $146.25 per month. Each says shipments occur every 28 days and a payment plan is available. The longer packages advertise 10% and 25% discounts, respectively. Their “3-month,” “6-month” and “12-month” labels should not be read as calendar-month durations.

For the six-month microdosing package, iThriveMD also claims $20 monthly savings, which does not exactly reconcile with its displayed $195 and $175.50 monthly equivalents. The longest package claims $48.75 monthly savings. More importantly, payment-plan availability is not a description of financing terms: the consulted pages do not identify a lender, interest, approval requirements or repayment schedule. Ask whether the alternative changes your total cost or leaves a separate payment obligation if clinical treatment stops.

This program includes a 30-minute initial consultation and monthly 15-minute follow-ups. Its page calls tirzepatide microdosing off-label and states that FDA has not specifically studied or approved those lower doses. Although some promotional language suggests fewer stomach problems, the page’s own FAQ acknowledges possible digestive or appetite-related effects. These statements do not establish comparative clinical effectiveness or freedom from side effects. Ask the clinician what evidence supports the particular proposal rather than treating the program label as reassurance.

Sources: [6] [1]

Which screening and lab requirements apply to you?

The published entry process starts with an online questionnaire about health and goals, followed by a clinical consultation reviewing diagnostic labs and a personalized plan. The general GLP page offers free eligibility assessments and says diabetes is not required. It describes adults with BMI over 27 and weight-related health conditions, or BMI over 30, as people who may qualify. Those are the provider’s general screening statements, not a guarantee of acceptance or a complete list of prescribing criteria.

Testing is a significant point to resolve. The homepage promises in-depth diagnostic testing and baseline labs before any plan begins. The general weight-loss page says each plan includes monthly consultations, metabolic lab testing and real-time progress tracking. Yet the microdosing page says no particular BMI or lab work is required to enroll. Enrollment and treatment initiation may be different steps, but the documentation does not explain the relationship. Ask exactly when testing is required for your selected service.

A practical consultation should also establish which tests are included, whether outside results are accepted and whether any testing creates an additional charge. Those details were not settled by the consulted documentation. NIDDK advises discussing medications, supplements, allergies and pregnancy plans with the treating clinician; BMI alone does not determine individual suitability. Bring those questions into the assessment rather than assuming that a free eligibility screen or a program’s easier enrollment language settles the clinical decision.

Sources: [7] [13] [10] [12] [6] [2]

Who supplies the medicine, and what evidence applies?

The semaglutide page says dispensing is handled by a LegitScript-certified facility, but the consulted extract does not identify that facility by name. The documentation does not establish the preparing and dispensing pharmacy’s address or license details. Certification language is a provider claim, not a substitute for identifying the pharmacy. Ask for its name, contact information and responsibility for preparation, labeling and medication questions. Also request the exact formulation and presentation; this review cannot establish those patient-specific details.

FDA’s relevant distinction is product-specific: compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That fact alone does not prove clinical inequivalence or establish the quality of a particular clinic. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Ask the prescriber how that recommendation applies to the proposed preparation rather than assuming approval transfers from a branded product.

iThriveMD’s own disclaimer acknowledges that compounded medicines have not been FDA reviewed or approved for safety or effectiveness and that reported results have not been independently verified. Published semaglutide and tirzepatide trials do not establish outcomes for this clinic, its compounded preparations or microdoses. A productive discussion separates the medicine’s identity, the reason it is proposed and the evidence for the particular use. Our medication questions before comparing an offer provide a framework without suggesting an individual treatment.

Sources: [7] [5] [1] [3] [4]

Can the clinic deliver the access and support you need?

The homepage advertises telehealth throughout California and Arizona with the same member pricing. Its location directory lists physical addresses in Roseville, Walnut Creek, Sunnyvale and Laguna Niguel, California; Scottsdale appears as “Telehealth Appointment.” That distinction matters if you want in-person instruction or injections. The consulted material does not support treating every location reference as a physical clinic or promise nationwide access. Confirm the specific appointment format available where you will receive care.

iThriveMD says eligible patients can begin treatment in clinic or at home, with progress tracked and plans adjusted as needed. Its tirzepatide page offers home shipment or clinic visits for support and injections, plus first-visit injection training, video tutorials and ongoing support. The semaglutide page advertises clinical oversight and coaching. These are useful documented services, but appointment availability, response times, clinical messaging channels and language assistance were not established. Ask how to reach the responsible clinician between scheduled consultations.

Shipping every 28 days describes a dispatch cadence, not an arrival date. The consulted pages do not specify carrier, shipping charges, temperature safeguards, transit time or replacement procedures. Ask who handles a delayed, damaged or temperature-compromised shipment before selecting home delivery. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. That instruction should remain separate from any assumption that a scheduled shipment guarantees usable medicine on arrival.

Sources: [10] [9] [7] [8] [1]

What happens if you change plans or want to stop?

The homepage says packages automatically renew at the interval associated with the selected package. A general notice separately says all memberships are charged every 28 days from their start date. Because package labels correspond to 12, 24 and 48 weeks, ask whether renewal refers to another full package purchase, a recurring membership charge or a different arrangement. The documentation does not reconcile these statements sufficiently to establish your next payment obligation without a program-specific agreement.

The consulted terms did not establish a cancellation method, minimum notice deadline, cancellation fees or refund rules. “No long-term commitment” on the monthly offer does not answer whether a charge already collected is refundable, and stopping renewal does not itself establish a refund right. Before paying, request written instructions identifying where to cancel, when cancellation becomes effective and what happens to unused services or medication orders. Our questions before the next charge can help distinguish these separate issues.

Also ask what happens financially if the clinician declines to prescribe, recommends a different program or later decides treatment should change. The public material does not settle those contingencies. A package’s stated duration does not, by itself, establish a guaranteed medication quantity or a clinical obligation to continue throughout it. These are not reasons to assume unfavorable terms; they are reasons to obtain the operative agreement before money and clinical expectations become tied to different interpretations.

Sources: [7] [8] [10] [5]

Which payment and responsibility details should be written down?

iThriveMD says it does not accept insurance for tirzepatide treatment and permits HSA or FSA payment. Its semaglutide wording is more conditional: patients may be able to use HSA/FSA funds, and the clinic can provide documentation for potential reimbursement if a plan includes out-of-network benefits. Neither statement guarantees reimbursement or account eligibility. Confirm separately with the health plan or account administrator; the clinic’s willingness to provide paperwork is different from a payer’s decision to cover the expense.

The tirzepatide page says its price remains the same regardless of dose. However, the general weight-loss page’s dose-dependent cost language creates a reason to confirm which pricing rule governs your purchase. Ask for an itemized statement covering medication, consultations, testing, coaching, supplies and delivery, with any separate charges identified. The public description of monthly consultations and metabolic testing is useful, but it does not conclusively establish that every advertised service is included without additional fees in every program.

Finally, iThriveMD publishes a referral disclosure naming Vishal Verma, MD, Samir Damani, MD, Empower Aesthetics Medical Group, Inc. and iThriveMD PC, and describing financial or service relationships among listed parties. That disclosure does not itself establish a problem, but it makes entity-level clarity worthwhile. Ask which organization bills you, which clinician manages treatment and which pharmacy handles dispensing concerns. Written answers turn a broad clinic offering into a service arrangement you can evaluate without relying on assumptions.

Sources: [10] [12] [8] [7]

Questions & answers

Can I enroll in iThriveMD without having diabetes?

Its general GLP program explicitly says diabetes is not required and offers a free eligibility assessment. The page describes adults with BMI over 27 plus weight-related health conditions, or BMI over 30, as potentially qualifying. That is not an exhaustive eligibility policy. Ask which criteria apply to the exact program, since microdosing has different published enrollment language.

Sources: [13] [6]

Is the $199 semaglutide price ongoing?

No. The monthly compounded injectable semaglutide offer lists $199 initially and $299 per month afterward, with billing every 28 days. The homepage limits the $100 promotion to the first month and excludes package purchases. Ask for the second charge date and amount in writing, especially if you switch between a monthly arrangement and a longer package.

Sources: [7] [10]

Does iThriveMD offer semaglutide microdosing?

Its general GLP FAQ says no: only tirzepatide is available through its microdosing protocols. It separately advertises semaglutide maintenance plans for people who have completed a full GLP weight-loss program. Ask the clinic to distinguish maintenance from microdosing in the proposed agreement, including the preparation, follow-up schedule and applicable price, rather than assuming those terms describe the same service.

Sources: [13]

Are lab tests required for every iThriveMD program?

The public statements differ. The homepage promises baseline labs before any plan starts, while the microdosing page says lab work is not required to enroll. The general weight-loss page also includes metabolic testing among plan services. Ask whether enrollment precedes a separate clinical screening step, which tests your program requires and whether those tests carry any additional charge.

Sources: [10] [6] [12]

Can I choose clinic visits instead of home delivery?

The tirzepatide page offers shipment to your door or clinic visits for support and injections. It also advertises injection instruction at the first visit, video tutorials and ongoing support. Confirm which physical location provides those services and how visits are scheduled. Scottsdale is listed as a telehealth appointment, so that directory entry alone does not establish an in-person Arizona clinic.

Sources: [8] [9]

Can I cancel a package and receive a refund?

The consulted documentation does not establish that right or its conditions. Packages are described as automatically renewing, and the homepage says payment is collected in full at purchase, although payment plans are also advertised. Request the cancellation deadline, required contact route, effective date and refund policy before purchasing. Cancellation of future renewal and reimbursement of money already collected are separate questions.

Sources: [10] [5] [7] [8] [6]

Our assessment

iThriveMD documents a recognizable service pathway: online intake, clinical consultation, compounded injectable medication when prescribed, and follow-up, with both telehealth and in-clinic options. It also publishes meaningful prices rather than requiring every prospective patient to start with an undisclosed quote. The strongest reasons for further questioning are specific: different testing statements, month-versus-week terminology, unclear standard-package totals, payment plans alongside full-payment language, an unnamed dispensing facility and incomplete cancellation terms. For a prospective patient, the useful next step is a written, program-specific explanation of the product, responsible clinician and pharmacy, complete charges, testing, support and renewal rules. Clear answers would make comparison more reliable; the public documentation alone does not settle those commitments or establish clinical results for iThriveMD’s compounded preparations.

Visit iThriveMD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

iThriveMD Review: Questions to Settle Before Choosing a GLP-1 Plan

At a glance

01Which iThriveMD service are you actually considering?

02What will the first payment—and the next one—cover?

03Does the microdosing offer answer a different question?

04Which screening and lab requirements apply to you?

05Who supplies the medicine, and what evidence applies?

06Can the clinic deliver the access and support you need?

07What happens if you change plans or want to stop?

08Which payment and responsibility details should be written down?